Key Drivers
- Cash Strength
- No Revenue
- Book Value Erosion
AIAI Summary
OLMA is now a catalyst-timing trade rather than a financing-survival story: its ~$505M cash and minimal debt give it runway, but the stock's real inflection depends on a convincing fall 2026 OPERA-01 readout, because continued burn and any clinical miss would quickly turn “well-funded” into dilution risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Strength
- •No Revenue
- •Book Value Erosion
OLMA has a very strong cash position and minimal debt, but zero revenue, persistent losses, and per-share book value erosion mean the investment case is driven more by liquidity than operating fundamentals.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support holding
- •Weak rebound
OLMA remains in a clear last month downtrend, with support near $13.42-$13.6 but overhead resistance at $14.6-$15.2 keeping any bounce tentative until momentum improves.
Fell about 19% from $16.82 to $13.59 over the last month
Sentiment & News
Key News Insights:
- •Clinical momentum
- •Board refresh
- •Hiring expansion
Olema Oncology is steadily advancing its pipeline and organization, with upcoming ASCO data on OP-3136, a Phase 3 OPERA-02 update, a new board appointment, and continued hiring.
These updates are modestly constructive, signaling steady execution across clinical, governance, and staffing fronts without a major strategic shift
Similar Companies in Healthcare
Other companies in the same sector with AI ratings